Evidence map›Paper›PMID 40045486›Full record

SynthesisClinical and translational medicine2025

Vascularised organoids: Recent advances and applications in cancer research.

Rui Zhou, Dagmar Brislinger, Julia Fuchs, Alicia Lyons, Sonja Langthaler, Charlotte A E Hauser, Christian Baumgartner

Abstract readSystematic Review
In one paragraph

Synthesis in Clinical and translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Re-Thinking Pharmacokinetics in Ovarian Cancer: What Do Organoids Add?International journal of molecular sciences · 2026
    Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Rui ZhouInstitute of Health Care Engineering with European Testing Center of Medical Devices, Graz University of Technology, Graz, Austria.
Dagmar BrislingerDepartment of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Medical University of Graz, Graz, Austria.
Julia FuchsInstitute of Health Care Engineering with European Testing Center of Medical Devices, Graz University of Technology, Graz, Austria.
Alicia LyonsInstitute of Health Care Engineering with European Testing Center of Medical Devices, Graz University of Technology, Graz, Austria.
Sonja LangthalerInstitute of Health Care Engineering with European Testing Center of Medical Devices, Graz University of Technology, Graz, Austria.
Charlotte A E HauserInstitute of Health Care Engineering with European Testing Center of Medical Devices, Graz University of Technology, Graz, Austria.
Christian BaumgartnerInstitute of Health Care Engineering with European Testing Center of Medical Devices, Graz University of Technology, Graz, Austria.ORCID 0000-0002-3763-5195

Funding

Austrian Cancer Aid/Styria - RESEARCHFORUM FF 2/2023
6 · The paper itself

Abstract

Organoids are three-dimensional (3D) cellular models designed to replicate human tissues and organs while preserving their physiological complexity and functionality. Among these, vascularised organoids represent a groundbreaking advancement in 3D tissue engineering, incorporating vascular networks into engineered tissues to more accurately mimic the in vivo tumour microenvironment. These models offer significantly improved physiological relevance compared to conventional two-dimensional cultures or animal models, positioning them as invaluable tools in cancer research. Despite their potential, the rapid proliferation of techniques and materials for developing vascularised organoids presents challenges for researchers navigating this dynamic field. This systematic review provides a comprehensive examination of methodologies for fabricating vascularised organoids, with a focus on strategies that enhance vascularisation and support organoid growth. It critically evaluates the materials used, emphasising those that effectively mimic the extracellular matrix and facilitate vascular network formation. Key advancements in engineered organoids models are highlighted, emphasising their potential for studying interactions between vasculature and cancer cells, conducting drug screening, and understanding cytokine regulation. In summary, this review provides an in-depth overview of the current landscape of vascularised organoid fabrication and functionality, addressing challenges and opportunities within the field. A detailed understanding of the scope and future trajectories is essential for advancing organoid development and expanding their applications in both basic cancer research and clinical practice. KEY POINTS: Comparative analysis: Evaluation of organoids, animal models, and 2D models, highlighting their respective strengths and limitations in replicating physiological conditions and studying disease processes. Vascularisation techniques: Comparative evaluation of vascularised organoid fabrication methods, emphasising their efficiency, scalability and ability to replicate physiological vascular networks. Material selection: Thorough evaluation of materials for vascularised organoid culture system, focusing on those that effectively mimic the extracellular matrix and support vascular network formation. Applications: Overview of organoid applications in basic cancer research and clinical settings, with an emphasis on their potential in drug discovery, disease modelling and exploring complex biological processes.

Indexed as

NeoplasmsOrganoidsTissue EngineeringAnimalsHumans3D tissue modelsangiogenesis and vasculogenesiscancer‐vasculature interactionsdrug testing platformsextracellular matrix (ECM)preclinical cancer modelstumour biology and cancer progressiontumour microenvironmentvascularised organoids

Identifiers

PMID40045486
PMCPMC11882480

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.